ANG II-induced hypertension in the VCD mouse model of menopause is prevented by estrogen replacement during perimenopause

Dennis P. Pollow, Melissa J. Romero-Aleshire, Jessica N. Sanchez, John Konhilas, Heddwen L Brooks

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Premenopausal females are resistant to the development of hypertension, and this protection is lost after the onset of menopause, resulting in a sharp increase in disease onset and severity. However, it is unknown how a fluctuating ovarian hormone environment during the transition from perimenopause to menopause impacts the onset of hypertension, and whether interventions during perimenopause prevent disease onset after menopause. A gradual transition to menopause was induced by repeated daily injections of 4-vinylcyclohexene diepoxide (VCD). ANG II (800 ng·kg-1·min-1) was infused into perimenopausal and menopausal female mice for 14 days. A separate cohort of mice received 17 β -estradiol replacement during perimenopause. ANG II infusion produced significantly higher mean arterial pressure (MAP) in menopausal vs. cycling females, and 17β-estradiol replacement prevented this increase. In contrast, MAP was not significantly different when ANG II was infused into perimenopausal and cycling females, suggesting that female resistance to ANG II-induced hypertension is intact during perimenopause. ANG II infusion caused a significant glomerular hypertrophy, and hypertrophy was not impacted by hormonal status. Expression levels of aquaporin-2 (AQP2), a collecting duct protein, have been suggested to reflect blood pressure. AQP2 protein expression was significantly downregulated in the renal cortex of the ANG II-infused menopause group, where blood pressure was increased. AQP2 expression levels were restored to control levels with 17 β -estradiol replacement. This study indicates that the changing hormonal environment in the VCD model of menopause impacts the severity of ANG II-induced hypertension. These data highlight the utility of the ovary-intact VCD model of menopause as a clinically relevant model to investigate the physiological mechanisms of hypertension that occur in women during the transition into menopause.

Original languageEnglish (US)
Pages (from-to)R1546-R1552
JournalAmerican Journal of Physiology - Regulatory Integrative and Comparative Physiology
Volume309
Issue number12
DOIs
StatePublished - 2015

Fingerprint

Perimenopause
Estrogen Replacement Therapy
Menopause
Hypertension
Aquaporin 2
Estradiol
Hypertrophy
Arterial Pressure
Blood Pressure
4-vinyl-1-cyclohexene dioxide
Ovary
Proteins
Down-Regulation
Hormones
Kidney
Injections

Keywords

  • Aquaporin-2
  • Collecting duct
  • Estrogen
  • Glomerular hypertrophy

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)

Cite this

ANG II-induced hypertension in the VCD mouse model of menopause is prevented by estrogen replacement during perimenopause. / Pollow, Dennis P.; Romero-Aleshire, Melissa J.; Sanchez, Jessica N.; Konhilas, John; Brooks, Heddwen L.

In: American Journal of Physiology - Regulatory Integrative and Comparative Physiology, Vol. 309, No. 12, 2015, p. R1546-R1552.

Research output: Contribution to journalArticle

@article{5b6d5c0f7e48464ba916f613c0dd05ff,
title = "ANG II-induced hypertension in the VCD mouse model of menopause is prevented by estrogen replacement during perimenopause",
abstract = "Premenopausal females are resistant to the development of hypertension, and this protection is lost after the onset of menopause, resulting in a sharp increase in disease onset and severity. However, it is unknown how a fluctuating ovarian hormone environment during the transition from perimenopause to menopause impacts the onset of hypertension, and whether interventions during perimenopause prevent disease onset after menopause. A gradual transition to menopause was induced by repeated daily injections of 4-vinylcyclohexene diepoxide (VCD). ANG II (800 ng·kg-1·min-1) was infused into perimenopausal and menopausal female mice for 14 days. A separate cohort of mice received 17 β -estradiol replacement during perimenopause. ANG II infusion produced significantly higher mean arterial pressure (MAP) in menopausal vs. cycling females, and 17β-estradiol replacement prevented this increase. In contrast, MAP was not significantly different when ANG II was infused into perimenopausal and cycling females, suggesting that female resistance to ANG II-induced hypertension is intact during perimenopause. ANG II infusion caused a significant glomerular hypertrophy, and hypertrophy was not impacted by hormonal status. Expression levels of aquaporin-2 (AQP2), a collecting duct protein, have been suggested to reflect blood pressure. AQP2 protein expression was significantly downregulated in the renal cortex of the ANG II-infused menopause group, where blood pressure was increased. AQP2 expression levels were restored to control levels with 17 β -estradiol replacement. This study indicates that the changing hormonal environment in the VCD model of menopause impacts the severity of ANG II-induced hypertension. These data highlight the utility of the ovary-intact VCD model of menopause as a clinically relevant model to investigate the physiological mechanisms of hypertension that occur in women during the transition into menopause.",
keywords = "Aquaporin-2, Collecting duct, Estrogen, Glomerular hypertrophy",
author = "Pollow, {Dennis P.} and Romero-Aleshire, {Melissa J.} and Sanchez, {Jessica N.} and John Konhilas and Brooks, {Heddwen L}",
year = "2015",
doi = "10.1152/ajpregu.00170.2015",
language = "English (US)",
volume = "309",
pages = "R1546--R1552",
journal = "American Journal of Physiology",
issn = "0363-6119",
publisher = "American Physiological Society",
number = "12",

}

TY - JOUR

T1 - ANG II-induced hypertension in the VCD mouse model of menopause is prevented by estrogen replacement during perimenopause

AU - Pollow, Dennis P.

AU - Romero-Aleshire, Melissa J.

AU - Sanchez, Jessica N.

AU - Konhilas, John

AU - Brooks, Heddwen L

PY - 2015

Y1 - 2015

N2 - Premenopausal females are resistant to the development of hypertension, and this protection is lost after the onset of menopause, resulting in a sharp increase in disease onset and severity. However, it is unknown how a fluctuating ovarian hormone environment during the transition from perimenopause to menopause impacts the onset of hypertension, and whether interventions during perimenopause prevent disease onset after menopause. A gradual transition to menopause was induced by repeated daily injections of 4-vinylcyclohexene diepoxide (VCD). ANG II (800 ng·kg-1·min-1) was infused into perimenopausal and menopausal female mice for 14 days. A separate cohort of mice received 17 β -estradiol replacement during perimenopause. ANG II infusion produced significantly higher mean arterial pressure (MAP) in menopausal vs. cycling females, and 17β-estradiol replacement prevented this increase. In contrast, MAP was not significantly different when ANG II was infused into perimenopausal and cycling females, suggesting that female resistance to ANG II-induced hypertension is intact during perimenopause. ANG II infusion caused a significant glomerular hypertrophy, and hypertrophy was not impacted by hormonal status. Expression levels of aquaporin-2 (AQP2), a collecting duct protein, have been suggested to reflect blood pressure. AQP2 protein expression was significantly downregulated in the renal cortex of the ANG II-infused menopause group, where blood pressure was increased. AQP2 expression levels were restored to control levels with 17 β -estradiol replacement. This study indicates that the changing hormonal environment in the VCD model of menopause impacts the severity of ANG II-induced hypertension. These data highlight the utility of the ovary-intact VCD model of menopause as a clinically relevant model to investigate the physiological mechanisms of hypertension that occur in women during the transition into menopause.

AB - Premenopausal females are resistant to the development of hypertension, and this protection is lost after the onset of menopause, resulting in a sharp increase in disease onset and severity. However, it is unknown how a fluctuating ovarian hormone environment during the transition from perimenopause to menopause impacts the onset of hypertension, and whether interventions during perimenopause prevent disease onset after menopause. A gradual transition to menopause was induced by repeated daily injections of 4-vinylcyclohexene diepoxide (VCD). ANG II (800 ng·kg-1·min-1) was infused into perimenopausal and menopausal female mice for 14 days. A separate cohort of mice received 17 β -estradiol replacement during perimenopause. ANG II infusion produced significantly higher mean arterial pressure (MAP) in menopausal vs. cycling females, and 17β-estradiol replacement prevented this increase. In contrast, MAP was not significantly different when ANG II was infused into perimenopausal and cycling females, suggesting that female resistance to ANG II-induced hypertension is intact during perimenopause. ANG II infusion caused a significant glomerular hypertrophy, and hypertrophy was not impacted by hormonal status. Expression levels of aquaporin-2 (AQP2), a collecting duct protein, have been suggested to reflect blood pressure. AQP2 protein expression was significantly downregulated in the renal cortex of the ANG II-infused menopause group, where blood pressure was increased. AQP2 expression levels were restored to control levels with 17 β -estradiol replacement. This study indicates that the changing hormonal environment in the VCD model of menopause impacts the severity of ANG II-induced hypertension. These data highlight the utility of the ovary-intact VCD model of menopause as a clinically relevant model to investigate the physiological mechanisms of hypertension that occur in women during the transition into menopause.

KW - Aquaporin-2

KW - Collecting duct

KW - Estrogen

KW - Glomerular hypertrophy

UR - http://www.scopus.com/inward/record.url?scp=84983095203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983095203&partnerID=8YFLogxK

U2 - 10.1152/ajpregu.00170.2015

DO - 10.1152/ajpregu.00170.2015

M3 - Article

C2 - 26491098

AN - SCOPUS:84983095203

VL - 309

SP - R1546-R1552

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0363-6119

IS - 12

ER -